Your session is about to expire
← Back to Search
JAK Inhibitor
CTP-543 8 mg BID for Alopecia Areata (THRIVE-AA2 Trial)
Phase 3
Waitlist Available
Research Sponsored by Concert Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and Baseline.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks 4, 8, 12, 16, 20, and 24
Awards & highlights
THRIVE-AA2 Trial Summary
This study is evaluating whether a drug can help people with alopecia areata.
Eligible Conditions
- Alopecia Areata
THRIVE-AA2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
The person has hair loss that is similar to alopecia areata, but the hair loss has been going on for at least 6 months and has not lasted more than 10 years
Select...
At least 50% of the scalp hair is lost, as measured by the SALT score, at the Screening and Baseline visits.
Select...
Eager to participate in the study and comply with all of the study's requirements.
THRIVE-AA2 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, weeks 4, 8, 12, 16, 20, and 24
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks 4, 8, 12, 16, 20, and 24
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24
Secondary outcome measures
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
+12 moreSide effects data
From 2022 Phase 3 trial • 706 Patients • NCT0451899512%
Headache
9%
Acne
6%
Blood creatine phosphokinase (increased)
5%
COVID-19
5%
Nasopharyngitis
3%
Upper respiratory tract infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CTP-543 8 mg BID
CTP-543 12 mg BID
THRIVE-AA2 Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: CTP-543 8 mg BIDExperimental Treatment1 Intervention
Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
Group II: CTP-543 12 mg BIDExperimental Treatment1 Intervention
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CTP-543
2021
Completed Phase 3
~2110
Find a Location
Who is running the clinical trial?
Concert PharmaceuticalsLead Sponsor
34 Previous Clinical Trials
3,894 Total Patients Enrolled
7 Trials studying Alopecia Areata
2,702 Patients Enrolled for Alopecia Areata
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Illinois
Florida
Texas
How old are they?
18 - 65
What site did they apply to?
Floridian Research Institute LLC
Dermatologists of Southwest Ohio
Progressive Clinical Research
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How responsive is this trial?
Typically responds via
Email
Share this study with friends
Copy Link
Messenger